IL285585A - fcmr-binding molecules and their uses - Google Patents

fcmr-binding molecules and their uses

Info

Publication number
IL285585A
IL285585A IL285585A IL28558521A IL285585A IL 285585 A IL285585 A IL 285585A IL 285585 A IL285585 A IL 285585A IL 28558521 A IL28558521 A IL 28558521A IL 285585 A IL285585 A IL 285585A
Authority
IL
Israel
Prior art keywords
fcmr
binding molecules
molecules
binding
Prior art date
Application number
IL285585A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of IL285585A publication Critical patent/IL285585A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285585A 2019-02-15 2021-08-12 fcmr-binding molecules and their uses IL285585A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806237P 2019-02-15 2019-02-15
PCT/CA2020/050195 WO2020163962A1 (en) 2019-02-15 2020-02-14 Fcmr-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
IL285585A true IL285585A (en) 2021-09-30

Family

ID=72043773

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285585A IL285585A (en) 2019-02-15 2021-08-12 fcmr-binding molecules and their uses

Country Status (14)

Country Link
US (1) US12286476B2 (enExample)
EP (1) EP3924388A4 (enExample)
JP (1) JP2022520817A (enExample)
KR (1) KR20210139273A (enExample)
CN (1) CN113993895A (enExample)
AU (1) AU2020222408A1 (enExample)
BR (1) BR112021016102A2 (enExample)
CA (1) CA3130225A1 (enExample)
EA (1) EA202192254A1 (enExample)
IL (1) IL285585A (enExample)
MX (1) MX2021009767A (enExample)
SG (1) SG11202108837WA (enExample)
TW (1) TWI857009B (enExample)
WO (1) WO2020163962A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
AU2014244444A1 (en) * 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
AU2014286869A1 (en) * 2013-07-03 2016-02-11 University Health Network Antibodies to Toso
US20150252434A1 (en) * 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
JP6877350B2 (ja) 2014-11-05 2021-05-26 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ２／３抗体及びその使用方法
EP3256163A4 (en) 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
EP3098237B1 (en) * 2015-05-28 2018-08-01 Universität Zu Köln Anti-toso chimeric antigen receptor and its use
EP3559042A4 (en) 2016-12-22 2020-11-25 Icahn School of Medicine at Mount Sinai ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF
MX2021009767A (es) 2019-02-15 2021-11-17 Univ Health Network Moleculas de union de fmcr y usos de las mismas.

Also Published As

Publication number Publication date
MX2021009767A (es) 2021-11-17
CN113993895A (zh) 2022-01-28
EP3924388A4 (en) 2023-02-15
EP3924388A1 (en) 2021-12-22
TW202035461A (zh) 2020-10-01
SG11202108837WA (en) 2021-09-29
CA3130225A1 (en) 2020-08-20
JP2022520817A (ja) 2022-04-01
KR20210139273A (ko) 2021-11-22
TWI857009B (zh) 2024-10-01
US12286476B2 (en) 2025-04-29
EA202192254A1 (ru) 2021-11-29
WO2020163962A1 (en) 2020-08-20
BR112021016102A2 (pt) 2021-11-09
AU2020222408A1 (en) 2021-09-09
US20220089725A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
IL294052B1 (en) Fluoroalkyl oxadiazoles and their uses
ZA202001113B (en) Anti-cd137 molecules and use thereof
IL301053B2 (en) Variants of hsd17b13 and their uses
IL269534A (en) Chimeric molecules and their uses
SG11202100935TA (en) Collagen-localized immunomodulatory molecules and methods thereof
IL289415A (en) Claudin-6 binding molecules and their use
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
IL287765A (en) TIGIT and FDI-1/TIGIT binding molecules
IL278019A (en) trans splicing molecules
ZA201806597B (en) Ilt7 binding molecules and methods of using the same
ZA202105847B (en) Mtroc modulators and uses thereof
IL284781A (en) LILRB3 binding molecules and uses thereof
IL278832A (en) Improved molecules that bind 41GP
SG11202006459XA (en) Proteinaceous molecules and uses therefor
IL287503B2 (en) Thio-semicarbazide compounds and their use
IL285585A (en) fcmr-binding molecules and their uses
IL311510A (en) D3 binding molecules and uses thereof
IL280369A (en) Myokines and their uses
EP4081255A4 (en) ANTI-CSF1R MOLECULES AND USES THEREOF
HK40068201A (en) Fcmr-binding molecules and uses thereof
GB201916288D0 (en) Dimeric molecules and uses thereof
HK40049522A (en) Optimized gp41-binding molecules and uses thereof
HK40064855A (en) Lilrb3-binding molecules and uses therefor
HK40033354A (en) Anti-cd137 molecules and use thereof